Rouillon F
Hôpital Albert Chenevier, Creteil, France.
Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S87-92. doi: 10.1016/s0924-977x(99)00027-9.
In the community, depression and anxiety are highly prevalent. The relationship between these two conditions is often unclear and has been the subject of much discussion. The classical viewpoint considered depression and anxiety to be two disorders with separate treatment options: anxiolytic agents for anxiety and antidepressant agents for depression. Depression and anxiety may occur together representing comorbid 'pure' conditions, or anxiety may predispose depression (or vice versa), or symptoms of anxiety and depression may be external manifestations of one underlying cause, or there may be an overlap of classifications. It is also possible that a mixed anxiety and depressive disorder exists: the association of subthreshold depressive symptoms and subthreshold depressive anxiety. This review examines the relationship of co-occurring depression and anxiety. The socioeconomic burden and the need for effective treatment of comorbid anxiety and depression are highlighted. The SSRIs, e.g. paroxetine, are discussed in particular as appropriate pharmacological therapy for anxiety with depression.
在社区中,抑郁症和焦虑症极为普遍。这两种病症之间的关系往往不明确,一直是诸多讨论的主题。传统观点认为抑郁症和焦虑症是两种需分别治疗的疾病:用抗焦虑药治疗焦虑症,用抗抑郁药治疗抑郁症。抑郁症和焦虑症可能同时出现,表现为共病的“单纯”病症,或者焦虑症可能诱发抑郁症(反之亦然),或者焦虑症和抑郁症的症状可能是同一潜在病因的外在表现,又或者可能存在分类上的重叠。也有可能存在混合性焦虑和抑郁障碍:阈下抑郁症状与阈下抑郁性焦虑的关联。本综述探讨了共病的抑郁症和焦虑症之间的关系。强调了社会经济负担以及有效治疗共病焦虑症和抑郁症的必要性。特别讨论了选择性5-羟色胺再摄取抑制剂(SSRIs),如帕罗西汀,作为治疗伴有抑郁症的焦虑症的合适药物疗法。